Biblio

Author Title [ Type(Desc)] Year
Filters: Author is Juliusson, Gunnar  [Clear All Filters]
Journal Article
Ravandi F, Kreitman RJ, Tiacci E, Andritsos L, Banerji V, Barrientos JC, Bhat SA, Blachly JS, Broccoli A, Call T, et al. Consensus opinion from an international group of experts on measurable residual disease in hairy cell leukemia. Blood Cancer J. 2022;12(12):165.
Eichhorst B, Niemann CU, Kater AP, Fürstenau M, von Tresckow J, Zhang C, Robrecht S, Gregor M, Juliusson G, Thornton P, et al. First-Line Venetoclax Combinations in Chronic Lymphocytic Leukemia. N Engl J Med. 2023;388(19):1739-1754.
Machaczka M, Johansson J-E, Remberger M, Hallböök H, Lazarevic VLj, Wahlin BEngelbrekt, Omar H, Wahlin A, Juliusson G, Kimby E, et al. High incidence of chronic graft-versus-host disease after myeloablative allogeneic stem cell transplantation for chronic lymphocytic leukemia in Sweden: graft-versus-leukemia effect protects against relapse. Med Oncol. 2013;30(4):762.
Gonzalez JMartin, Baudet A, Abelechian S, Bonderup K, D'Altri T, Porse B, Brakebusch C, Juliusson G, Cammenga J. A new genetic tool to improve immune-compromised mouse models: Derivation and CRISPR/Cas9-mediated targeting of NRG embryonic stem cell lines. Genesis. 2018.
Wålinder G, Samuelsson J, Näsman P, Hansson M, Juliusson G, Forsberg K, Svensson R, Linder O, Carlson K, Kristinsson SY, et al. Outcome and characteristics of non-measurable myeloma: A cohort study with population-based data from the Swedish Myeloma Registry. Eur J Haematol. 2019.
Bhoi S, Ljungström V, Baliakas P, Mattsson M, Smedby KE, Juliusson G, Rosenquist R, Mansouri L. Prognostic impact of epigenetic classification in chronic lymphocytic leukemia: the case of subset #2. Epigenetics. 2016.
Juliusson G, Jadersten M, Deneberg S, Lehmann S, Möllgård L, Wennström L, Antunovic P, Cammenga J, Lorenz F, Ölander E, et al. The prognostic impact of FLT3-ITD and NPM1 mutation in adult AML is age-dependent in the population-based setting. Blood Adv. 2020;4(6):1094-1101.
Ngai LLam, Hanekamp D, Janssen F, Carbaat-Ham J, Hofland MAM, Fayed MMHE, Kelder A, van Marsbergen LOudshoorn-, Scholten WJ, Snel AN, et al. Prospective Validation of the Prognostic Relevance of CD34+CD38- AML Stem Cell frequency in the HOVON-SAKK132 trial. Blood. 2023.
Nilsson C, Hulegårdh E, Garelius H, Möllgård L, Brune M, Wahlin A, Lenhoff S, Frödin U, Remberger M, Höglund M, et al. Secondary acute myeloid leukemia and the role of allogeneic stem cell transplantation in a population-based setting. Biol Blood Marrow Transplant. 2019.
Roschupkina T, Juliusson G. Subpopulations of T regulatory cells in blood stem cell harvests influence development of acute graft vs. host disease in allogeneic transplant recipients. Cytometry B Clin Cytom. 2016.
Bhoi S, Baliakas P, Cortese D, Mattsson M, Engvall M, Smedby KE, Juliusson G, Sutton L-A, Mansouri L. UGT2B17 expression: a novel prognostic marker within IGHV-mutated chronic lymphocytic leukemia?. Haematologica. 2015.
Juliusson G. Venetoclax with intensive chemotherapy in younger patients with acute myeloid leukaemia. Lancet Haematol. 2022;9(5):e317-e318.